We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Magnetic Nanoparticles Simultaneously Diagnose, Monitor, and Treat Diseases

By LabMedica International staff writers
Posted on 21 Nov 2009
Tiny magnetic nanoparticles (mNPs) and external magnetic forces create a medical means to confirm specific ailments and automatically release healing drugs while inside a living system. More...
For example, mNPs can direct ”therapeutically armed” white blood cells to invade a tumor's territory, or they can target specific nerve channels and induce nerve-led behavior (such as heart beating).

The magnetic component of the direction-giving nanoparticles is usually an iron-based compound called ferric oxide, which is coated in a biocompatible surface, sometimes using, for example, fatty acids, to provide stability during the particles journey through the body. For biomedicine, the particles are useful because specific signal triggering molecules can be added to identify certain conditions, or dyes to help in medical imaging, or therapeutic agents to remedy a wide range of conditions.

Multifunctional particles, modeled on viral particles such as the flu and human immunodeficiency virus (HIV), are being studied and developed to carry signal-generating sub-molecules and drugs.

A number of review articles dealing with progress in the use of mNPs in biomedicine as well as their future prospects were published on November 6, 2009 in IOP Publishing's Journal of Physics D.

Professor Q. Pankhurst from the department of physics and astronomy at the University College London (UK) and colleagues were authors of one of the reviews, which dealt with the progress in applications of mNPs. In their conclusion they wrote, "there is a lot of activity in this field, and the future is bright, so long as we pay attention to the primary criteria for success, making sure that there is a clearly identified clinical need that can be addressed, and addressed in a way that can be quantified or assessed to the satisfaction of the relevant licensing bodies.''

Related Links:

University College London



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Automated Urinalysis Solution
UN-9000
New
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.